445 related articles for article (PubMed ID: 29269870)
41. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
42. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
43. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
44. GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner.
Xia Z; Zhang X; Liu P; Zhang R; Huang Z; Li D; Xiao X; Wu M; Ning N; Zhang Q; Zhang J; Liu M; Jiao B; Ren R
Cell Death Dis; 2021 Jan; 12(1):54. PubMed ID: 33423045
[TBL] [Abstract][Full Text] [Related]
45. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
46. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
47. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
48. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Bucher P; Erdmann T; Grondona P; Xu W; Schmitt A; Schürch C; Zapukhlyak M; Schönfeld C; Serfling E; Kramer D; Grau M; Klener P; Lengerke C; Schulze-Osthoff K; Lenz G; Hailfinger S
Blood; 2020 Jan; 135(2):121-132. PubMed ID: 31794606
[TBL] [Abstract][Full Text] [Related]
49. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
50. Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
Zhu F; Crombie JL; Ni W; Hoang NM; Garg S; Hackett L; Chong SJF; Collins MC; Rui L; Griffin J; Davids MS
Haematologica; 2024 Jan; 109(1):186-199. PubMed ID: 37534528
[TBL] [Abstract][Full Text] [Related]
51. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
52. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
53. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
[TBL] [Abstract][Full Text] [Related]
54. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Montraveta A; Xargay-Torrent S; Rosich L; López-Guerra M; Roldán J; Rodríguez V; Lee-Vergés E; de Frías M; Campàs C; Campo E; Roué G; Colomer D
Oncotarget; 2015 Aug; 6(25):21159-72. PubMed ID: 26110568
[TBL] [Abstract][Full Text] [Related]
55. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
56. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
57. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Peperzak V; Slinger E; Ter Burg J; Eldering E
Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
[TBL] [Abstract][Full Text] [Related]
58. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
[TBL] [Abstract][Full Text] [Related]
59. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
60. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]